anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: virology, veterinary science. SUBSTANCE: invention relates to preparing serum for serodiagnosis of foot and mouth disease type A and serum is obtained from guinea pigs and rabbits. Preliminary animal-donors are infected with adapted virus, subjected their for hyperimmunization and an antigen-containing material from the strain N 1707 "Armenia- -98" and adjuvant as components of the preparation are administrated. Periodicity and amount of doses is determined as sufficient to form specific antibodies in animal-donors blood. Virus used for hyperimmunization is cultured in the suspension culture of cells VNK-21, obtained virus is purified, concentrated and inactivated. For hyperimmunization of animal-donors antigen (activity in RSK is 1:16, not less) is used. Saponin, its analogs or oily adjuvants are used as an adjuvant. In 10 days after hyperimmunization animal-donors are subjected for bleeding and blood serum is obtained. EFFECT: increased activity and specificity of the preparation. 2 cl, 2 dwg, 4 tbl, 2 ex
PCT No. PCT/JP85/00654 Sec. 371 Date Jul. 28, 1986 Sec. 102(e) Date Jul. 28, 1986 PCT Filed Nov. 27, 1985 PCT Pub. No. WO86/03198 PCT Pub. Date Jun. 5, 1986.Compounds of the formula:  <IMAGE>  wherein R1 represents fluorine atom at the para position, chlorine atom at the para position, methyl group at the para position or trifluoromethyl group at the para or meta position; and R2 represents hydrogen atom, methyl group, ethyl group, 2-hydroxyethyl group or 3-hydroxypropyl group, provided that R2 represents ethyl group, 2-hydroxyethyl group or 3-hydroxypropyl group when R1 represents fluorine atom at the para position, methyl group at the para position or trifluoromethyl group at the para position, and a pharmaceutically acceptable salt therof, process for the preparation thereof, and pharmaceutical composition containing the same. The compounds and pharmaceutically acceptable salts thereof show excellent cytoprotective effect and useful for prophylaxis and treatment of peptic ulcer and inflammatory gastrointestinal diseases.
Inflammation is an important biological process initiated by the immune system in response to injury, irritation or infection. Prolonged or chronic inflammation is involved in the etiology of several diseases such as cardiovascular disease (CVD), diabetes, rheumatoid arthritis, cancer, and neurodegenerative diseases such as Alzheimer disease. The evidence base clearly demonstrates benefits of diet in ameliorating inflammation and reducing the burden of chronic disease. With respect to marine-derived omega-3 fatty acids and various markers of inflammation related to cardiovascular disease (CVD), both population studies and randomized controlled supplementation trials have yielded mixed results.

Some studies have demonstrated a dose-response relationship between dietary eicosapentaenoic acid and docosahexaenoic acid (EPA + DHA) and increased membrane (phospholipid) EPA and DHA. Red blood cell (RBC) EPA + DHA content has been proposed as a potential, modifiable marker for coronary heart disease (CHD) risk. It is well established that these fatty acids are precursors of series-3 prostanoids, thromboxanes, 5-series leukotrienes, and novel lipid mediators such as resolvins and protectins that have anti-inflammatory effects. We hypothesize that nutritionally-relevant intakes of omega-3 fatty acids are able to blunt the usual response to an inflammatory stimulus. We propose to test this hypothesis using both in vivo (i.v. endotoxin challenge) and ex vivo (endotoxin-stimulated monocytes) models in a 6-month, dose-response study with marine-derived omega-3 fatty acid supplements in healthy volunteers.
Methods 39 Medical Wards and 12 Emergency Departments, belonging to 12 hospitals, were voluntarily enrolled. Through the collaboration of 12 Multidisciplinary Teams (MT), we took a Pre-EOI picture of the human resources (i.e. doctors to patients ratio) and of the organisational structures (i.e. laboratory's opening hours) of each hospital. For six months, each unit enrolled was asked to fill in a Clinical Checklist for every patient suspected for severe sepsis or septic shock; so that the Pre-EOI "sepsis six" bundle compliance could be evaluated. Then, we planned several pre-agreed educational meetings for all of the doctors and nurses belonging to the enrolled wards. In the meanwhile the MT worked to overcome any impediment to a better septic patient management. Finally, the educated medical staff was asked to fill in again the same Clinical Checklist used in the Pre-EOI phase; so that the Post-EOI "sepsis six" bundle compliance could be evaluated and a comparison with the Pre-EOI phase could be done.

Hypothesis This is the first study aimed to analyze the impact of an Educational and Organizational Intervention in the outcome of septic patients managed in no Critical Care Units. We guess that the differences showed in human resources and organizational structures among the hospitals could have a role in the "sepsis six" bundle compliance and in the patient's outcome, but only a comparison with data collected from the clinical checklist and patient's outcome will confirm our guess. Likewise, we believe that an educational intervention could improve the septic patient's management, but we need the Post-EOI phase conclusion to demonstrate or not our hypothesis.
BACKGROUND AND PURPOSE: Whilst sleep disturbances are associated with stroke, their association with stroke severity is less certain. In the INTERSTROKE study, the association of pre-morbid sleep disturbance with stroke severity and functional outcome following stroke was evaluated.
METHODS: INTERSTROKE is an international case-control study of first acute stroke. This analysis included cases who completed a standardized questionnaire concerning nine symptoms of sleep disturbance (sleep onset latency, duration, quality, nocturnal awakening, napping duration, whether a nap was planned, snoring, snorting and breathing cessation) in the month prior to stroke (n = 2361). Two indices were derived representing sleep disturbance (range 0-9) and obstructive sleep apnoea (range 0-3) symptoms. Logistic regression was used to estimate the magnitude of association between symptoms and stroke severity defined by the modified Rankin Score.
RESULTS: The mean age of participants was 62.9 years, and 42% were female. On multivariable analysis, there was a graded association between increasing number of sleep disturbance symptoms and initially severe stroke (2-3, odds ratio [OR] 1.44, 95% confidence interval [CI] 1.07-1.94; 4-5, OR 1.66, 95% CI 1.23-2.25; >5, OR 2.58, 95% CI 1.83-3.66). Having >5 sleep disturbance symptoms was associated with significantly increased odds of functional deterioration at 1 month (OR 1.54, 95% CI 1.01-2.34). A higher obstructive sleep apnoea score was also associated with significantly increased odds of initially severe stroke (2-3, OR 1.48; 95% CI 1.20-1.83) but not functional deterioration at 1 month (OR 1.19, 95% CI 0.93-1.52).
CONCLUSIONS: Sleep disturbance symptoms were common and associated with an increased odds of severe stroke and functional deterioration. Interventions to modify sleep disturbance may help prevent disabling stroke/improve functional outcomes and should be the subject of future research.
Pediatric patients who are operated under general anesthesia using automated gas flow which is set to speed 8 to achieve targeted end-expiratory sevoflurane concentration (MAC 1.2) will be included in the study. Automated gas flow provides a gas mixture in different proportions which is automatically generated and consists of sevoflurane, oxygen and air. Inspired and end-tidal concentrations of sevoflurane, oxygen and air will be available on the anesthesia ventilator screen which will be recorded accordingly in15-minute intervals.
AIM: Exercise can reduce body weight and promote white fat browning, but the underlying mechanisms remain largely unknown. This study investigated the role of fibronectin type III domain-containing protein 5 (FNDC5)/Irisin, a hormone released from exercising muscle, in the browning of white fat in circulating extracellular vesicles (EVs).
METHODS: Mice were subjected to a 4 weeks of running table exercise, and fat browning was analyzed via histology, protein blotting and qPCR. Circulating EVs were extracted by ultrahigh-speed centrifugation, and ELISA was used to measure the irisin concentration in the circulating EVs. Circulating EVs that differentially expressed irisin were applied to adipocytes, and the effect of EV-irisin on adipocyte energy metabolism was analyzed by immunofluorescence, protein blotting, and cellular oxygen consumption rate analysis.
RESULTS: During sustained exercise, the mice lost weight and developed fat browning. FNDC5 was induced, cleaved, and secreted into irisin, and irisin levels subsequently increased in the plasma during exercise. Interestingly, irisin was highly expressed in circulating EVs that effectively promoted adipose browning. Mechanistically, the circulating EV-irisin complex is transported intracellularly by the adipocyte membrane receptor integrin αV, which in turn activates the AMPK signaling pathway, which is dependent on mitochondrial uncoupling protein 1 to cause mitochondrial plasmonic leakage and promote heat production. After inhibition of the AMPK signaling pathway, the effects of the EV-irisin on promoting fat browning were minimal.
CONCLUSION: Exercise leads to the accumulation of circulating EV-irisin, which enhances adipose energy metabolism and thermogenesis and promotes white fat browning in mice, leading to weight loss.
In clinical treatment and research, the applied doses of Conbercept in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Conbercept ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
The invention discloses a traditional Chinese medicine composition for patients suffering from liver-kidney yin deficiency-type epistaxis. Active ingredients of the traditional Chinese medicine composition comprise 30-45g of wolfberry, 20-30g of Chinese chive seed, 20-30g of himalayan teasel root, 20-30g of eucommia, 10-20g of red peony root, 10-20g of unprocessed rehmannia root, 10-20g of reed rhizome, 10-20g of bamboo leaf, 10-20g of cape jasmine, 10-20g of chrysanthemum, 10-20g of madder, 10-20g of curcuma tuber, 10-20g of fructus psoraleae and 10-20g of Chinese angelica. The traditional Chinese medicine composition is prepared by simple processes, has effects of nourishing liver and kidney, and cooling blood and stopping blood, and can effectively treat liver-kidney yin deficiency-type epistaxis. The traditional Chinese medicine composition mainly comprises the traditional Chinese medicine ingredients acting on liver and kidney. The traditional Chinese medicine composition has balanced medicine properties and satisfies a combination principle of a formula comprising one monarch drug, three minister drugs and nine assistant drugs. Based on 86 patients suffering from liver-kidney yin deficiency-type epistaxis, the traditional Chinese medicine composition has an effective rate of 91.8% and a good effect rate of 87.2%.
Acute pancreatitis is among the most common gastrointestinal diseases, and a major cause of hospitalization and morbidity. Gallstones and alcohol abuse are the most common causes of acute pancreatitis. Other etiologies include hypertriglyceridemia, medications, post- endoscopic retrograde cholangiopancreatography (ERCP), trauma, hypercalcemia, infections and toxins, anatomic anomalies, etc. In most cases acute pancreatitis is a mild self-limiting disease. However, up to 20% of patients develop severe pancreatitis with pancreatic necrosis, which possess high rates of multi-organ failure and mortality. Conservative management of acute necrotizing pancreatitis includes fluid resuscitation, nutritional support, and broad spectrum antibiotics for infected necrotic peripancreatic fluid collection (PFC). Indications for further invasive interventions include infected necrotic PFC and/or persistent severe symptoms due to mass effect. Current clinical management algorithms favor endoscopic ultrasound (EUS)-guided drainage of PFCs. In case of a large collection or extension to the paracolic gutters, a percutaneous drainage is indicated. Dual modalities (percutaneous together with endoscopic drainage) possess lower rates of pancreatic-cutaneous fistulas, shorter length of hospitalization and less endoscopic interventions. Direct endoscopic necrosectomy should be considered when the patient fails to improve despite endoscopic and percutaneous drainage. A multidisciplinary approach, which involves advanced endoscopists, interventional radiologists, pancreaticobiliary surgeons as well as nutrition and infectious disease specialists, is needed for the optimal management of severe necrotizing pancreatitis.
Disclosed is a wound scar-free repairing medicinal liquor wet tissue. The wound scar-free repairing medicinal liquor wet tissue is prepared from 1 part of radix clematidis, 1 part of cassis twig, 1 part of unprocessed semen strychni, 1 part of asarum sieboldi mig, 1 part of pawpaw, 1 part of notopterygium root, 1 part of radix angelicae tuhuo, 1 part of ligusticum wallichii, 1 part of radix angelicae, 1 part of asarum sieboldi mig, 1 part of angelica sinensis, 1 part of the bark of eucommia, 1 part of the root of bidentate achyranthes, 1 part of dipsacus root, 1 part of paris polyphylla, 1.2 parts of frankincense, 1.2 parts of myrrh, 0.5 part of unprocessed radix aconiti kusnezoffii, 0.5 part of unprocessed radix aconiti, 0.6 part of unprocessed arisaema consanguineum schott and 0.7 part of fenugreek. The 1.2 parts of frankincense and the 1.2 parts of myrrh are mixed by mature vinegar for processing drugs. The 0.6 part of unprocessed arisaema consanguineum schott and the 0.7 part of fenugreek are smashed and soaked by wine, then medicinal liquor is obtained through filtration, and the medicinal liquor has high comprehensive effects of diminishing inflammation, shifting poison, removing rotting and promoting freshness, stimulating the menstrual flow and activating veins. Then a water absorption hygienic material is used for being soaked with the medicinal liquor, so that a medicinal liquor wet tissue bag is made. The medicinal liquor wet tissue is externally applied to a wound directly, scar-free repairing is achieved in human body injury wound treatment for healing, normal skin can be covered after the wound is healed, the using occasion is unlimited, and the wound scar-free repairing medicinal liquor wet tissue can be applied to various different injuries in a clinical treatment healthcare working chamber and a living and working environment anytime and anywhere.
PCT No. PCT/EP95/00147 Sec. 371 Date Sep. 17, 1996 Sec. 102(e) Date Sep. 17, 1996 PCT Filed Jan. 13, 1995 PCT Pub. No. WO95/19371 PCT Pub. Date Jul. 20, 1995A host cell which is provided with a S-layer comprising a fusion polypeptide consisting essentially of: (a) at least sufficient of a S-layer protein for a S-layer composed thereof to assemble, and (b) a heterologous polypeptide which is fused to either the carboxy terminus of (a) or the amino terminus of (a) and which is thereby presented on the outer surface of the said cell; can be used as a vaccine, for screening for proteins and antigens and as a support for immobilizing an enzyme, peptide or antigen. A process of transforming B. Sphaericus cells comprising electroporation is also provided.
Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
The starting dose of ivabradine was 5 mg twice daily (BID), although investigators had the discretion to start participants at 2.5 mg BID if participant had a history of conduction defects, or bradycardia that could lead to hemodynamic compromise. Dose was adjusted at Day 15 (and at any other clinical visit) between 2.5 - 7.5 mg BID based on heart rate and signs/symptoms of bradycardia.
PURPOSE:To obtain a diabetic remedy having excellent lowering activity against amount of blood sugar, comprising dried powder or an extract of earthworm as an active ingredient. CONSTITUTION:Castings in digestive tube of live earthworm are vomited, dirt attached to the earthworm is washed with water, removed or the above- mentioned operations are carried out in the reverse order. The earthworm is ground in a wet state to give a suspension, which is frozen at -10--60 deg.C. Then freezing and vacuum drying are carried out in a temperature range of -60-80 deg.C at <=10mmHg degree of vacuum for 10-100hr while stepwise raising temperature and the final process of the freezing and vacuum drying is done at 70-80 deg.C for 0.01-0.5mmHg for 5-10hr to give dried powder of earthworm. The suspension or the dried powder in the operation is extracted with an extractant selected from an aqueous solvent, a water-miscible solvent or a water- immiscible organic solvent and the extracting solvent is removed to give an extract. A diabetic remedy contains the dried powder or the extract obtained by the operation.
FIELD: hygiene.SUBSTANCE: present invention relates to compositions for oral care. Disclosed composition contains a) basic amino acid in free or salt form, where basic amino acid is selected from arginine, lysine and their combination; b) a combination of zinc ion sources and c) a thickening system comprising i) 0.4 wt. % or 0.7 wt. % hydroxyethyl cellulose having a molecular weight of 300,000 to 350,000, and ii) 0.5 wt. % or 0.7 wt. % of xanthan gum.EFFECT: composition demonstrates ability to avoid loss of viscosity and maintain static yield strength for a long period of time.10 cl, 12 tbl, 8 ex
1526205 Stabilizing interferon G D SEARLE & CO Ltd 31 Oct 1975 [7 Nov 1974] 48135/74 Heading A5B Aqueous interferon preparations are stabilized against inactivation due to mechanical stress, (i.e. the biological inactivation caused by conditions encountered during purification, concentration, packaging procedures, filtration and storage, probably due to formation of sulphydryl group interlinkage or dissulphide interchange reactions to form inter- or intra-molecular disulphide bridges), by treatment with an agent which will selectively retain interferon sulphydryl groups in the reduced state but not reduce essential disulphide linkages, or an agent which will selectively block interferon sulphydryl groups. Suitable agents retaining sulphydryl groups in a reduced state are reduced glutathione, thiodiglycol, thioethanolamine, C 1-7  thioalkanoic acids, monothioglycerol, dithiotreietol, thioctic acid, cysteine, N-acetylcysteine and N- acetyl homocysteine. These materials may subsequently be removed from the interferon solution by dialysis against a buffer solution. Agents which block the interferon sulphydryl groups are pchloromercuribenzoate and phydroxymercuribenzoate, which cannot be removed by dialysis. The interferon preparation may be produced from a fibroblast cell culture.
The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19xCD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1 :5 or lower is indicative for a risk of potential adverse effects for said patient or determining the total B cell count of said patient, wherein a total B cell count of less than about 50 B cells per microliter of peripheral blood is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19xCD3 bispecific antibody to a human patient having a B:T cell ratio of about 1 :5 or lower and/or a total B cell count of less than about 50 B cells per microliter of peripheral blood, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose. In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use of a CD19xCD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well.
The association of air pollution and greenspace with respiratory pathogen acquisition and respiratory health was investigated in a community-based birth-cohort of 158 Australian children. Weekly nasal swabs and daily symptom-diaries were collected for 2-years, with annual reviews from ages 3-7-years. Annual exposure to fine-particulate-matter (PM2.5), nitrogen-dioxide (NO2), and normalised-difference-vegetation-index (NDVI) was estimated for pregnancy and the first 2-years-of-life. We examined rhinovirus, any respiratory virus, Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae detections in the first 3-months-of-life, age at initial pathogen detection, wheezing in the first 2-years, and asthma at ages 5-7-years. Our findings suggest that higher NDVI was associated with fewer viral and M. catarrhalis detections in the first 3-months, while increased PM2.5 and NO2 were linked to earlier symptomatic rhinovirus and H. influenzae detections, respectively. However, no associations were observed with wheezing or asthma. Early-life exposure to air pollution and greenspace may influence early-life respiratory pathogen acquisition and illness.  .
PURPOSE: A Lactobacillus casei HY7211 and a product containing the same are provided to prevent and treat allergic diseases. CONSTITUTION: A Lactobacillus casei HY7211(deposit number: KCTC 11721BP) has immunomodulatory efficiency. The strain control immunity by suppressing IgE(immunoglobulin E) expression. A pharmaceutical composition for preventing or treating allergic disease contains the strain as an active ingredient. Fermented milk contains the strain as an active ingredient. A health functional food contains the strain as an active ingredient.
The invention relates to a traditional Chinese medicine used for treating erosive hemorrhagic gastritis. The invention mainly aims at overcoming the defects in the prior art and solving the problems that the curative effect is poor and relapse is easily caused. The traditional Chinese medicine provided by the invention comprises the following raw materials in parts by weight: 15-45 parts of crude white paeony root, 12-36 parts of bletilla striata, 5-15 parts of ampelopsis japonica, 3-9 parts of pseudo-ginseng, 7-21 parts of coptis root, 5-15 parts of liquorice, 2-6 parts of dragon's blood and 1-3 parts of snake slough. The traditional Chinese medicine provided by the invention has an obvious curative effect when being used for treating erosive hemorrhagic gastritis, relapse is hardly caused and no toxic or side effect is produced. 37 patients are observed by virtue of clinic treatment, and the total effective rate is 97.30%. 33 patients are contained in a control group, and the total effective rate is 72.72%.